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Effect of Compression Force on Agglomeration of Micronized Active
Pharmaceutical Ingredients: Techniques to Prevent API Agglomeration During
Compression
Abstract
Micronization is one of the common processes for size reduction to increase surface area of poorly
soluble Active Pharmaceutical Ingredient’s (API). This size reduction improves the dissolution rate and
permeability thereby increasing the bioavailability for hydrophobic API’s.
Tablets and capsules are the most marketed and easy to manufacture solid dosage forms. During
manufacturing of tablets, high compression forces are applied uniaxially on the powder bed to get a
coherent consolidated compact with good tensile strength. So, diluents are required to mix with API’s and
compress into tablets. When this mixture is compressed into tablets, there is a possibility of
agglomeration of micronized API to API particles together within the tablet due to their high surface area
and high surface free energy during compression. Increasing the particle size and decreasing the surface
is generally expected to decrease the dissolution rate of the API.
Micronized furosemide and griseofulvin were used as model API’s based on the biopharmaceutical
classification system to study the effect of compression force on particle agglomeration during
compression and also to study the processes and materials to prevent that agglomeration. The size of
furosemide and griseofulvin particles was measured after disintegration of tablets compressed by
varying compression forces and drug loading. Effect of size of diluents on agglomeration of API’s was
also studied by varying the size of diluents like lactose mono hydrate and dicalcium phosphate dihydrate.
The bonding mechanism for formation of agglomerates of these API’s during compression was studied
by comparing the tensile strength of the compacts soaked and dried in solvents of various dielectric
media. Prevention of micronized particle agglomeration during compression was studied by using
particle agglomeration inhibitors like PEG 3350, Lutrol F68 micro, hydroxyl propyl starch polymer and by
various treatment methods like physical mixing, hexane slurry method, roller compaction and spray
drying. The particles were characterized for change in crystal structure, polymorphism and surface
morphology by X-ray diffraction, thermal studies and microscopy studies.
Micronized furosemide and griseofulvin particle size was increased significantly and linearly by
increasing the drug loading and compression force during compression. The size of the formed
agglomerates was directly proportional to particle size of diluents. The dominating bonding mechanism
responsible for agglomerate formation was found to be solid bridge formation between drug particles
during compression. The API to API particle agglomeration during compression was successfully
prevented by using particle agglomeration inhibitors (PAI’s). Treatment with hexane and increase in the
level of super disintegrant provided limited prevention of agglomeration during compression for
furosemide particles. The spray drying with either mannitol or hydroxy propyl starch for micronized
furosemide significantly reduced the agglomeration of API particles during compression. Roller
compaction process with Lutrol F68 micro and PEG 3350 provided significant reduction in the
agglomeration of drug particles for both the API’s during compression. Compression force and treatment
with PAI’s on polymorphism was observed in changing the crystal structure and polymorphism during
compression and confirmed by thermal and X-ray crystallographic studies for both the API’s. Scanning
Electron Microscopy studies revealed compression force and roller compaction process with PAI’s
changed the surface morphology of both the API’s.
The results of the above studies indicated that compression of micronized hydrophobic poorly soluble
drugs into tablets affects the dissolution rate due to agglomeration of API. The micronization process for
improving the dissolution rate of poorly soluble drugs showed disadvantageous with respect to tablets

compressed at high compression forces because of agglomeration of furosemide and griseofulvin
particles during compression. Hence control of particle size and selection of size of diluents are
necessary during formulation of tablets of hydrophobic poorly soluble drugs. Primary particle size
increase of micronized hydrophobic drugs during compression can also be minimized by treatment with
particle agglomeration inhibitors prior to compression.
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ABSTRACT
Micronization is one of the common processes for size reduction to increase
surface area of poorly soluble Active Pharmaceutical Ingredient’s (API). This size
reduction improves the dissolution rate and permeability thereby increasing the
bioavailability for hydrophobic API’s.
Tablets and capsules are the most marketed and easy to manufacture solid dosage
forms. During manufacturing of tablets, high compression forces are applied uniaxially
on the powder bed to get a coherent consolidated compact with good tensile strength. So,
diluents are required to mix with API’s and compress into tablets. When this mixture is
compressed into tablets, there is a possibility of agglomeration of micronized API to API
particles together within the tablet due to their high surface area and high surface free
energy during compression. Increasing the particle size and decreasing the surface is
generally expected to decrease the dissolution rate of the API.
Micronized furosemide and griseofulvin were used as model API’s based on the
biopharmaceutical classification system to study the effect of compression force on
particle agglomeration during compression and also to study the processes and materials
to prevent that agglomeration. The size of furosemide and griseofulvin particles was
measured after disintegration of tablets compressed by varying compression forces and
drug loading. Effect of size of diluents on agglomeration of API’s was also studied by
varying the size of diluents like lactose mono hydrate and dicalcium phosphate dihydrate.
The bonding mechanism for formation of agglomerates of these API’s during
compression was studied by comparing the tensile strength of the compacts soaked and
dried in solvents of various dielectric media. Prevention of micronized particle
agglomeration during compression was studied by using particle agglomeration inhibitors
like PEG 3350, Lutrol F68 micro, hydroxyl propyl starch polymer and by various
treatment methods like physical mixing, hexane slurry method, roller compaction and
spray drying. The particles were characterized for change in crystal structure,
polymorphism and surface morphology by X-ray diffraction, thermal studies and
microscopy studies.
Micronized furosemide and griseofulvin particle size was increased significantly
and linearly by increasing the drug loading and compression force during compression.
The size of the formed agglomerates was directly proportional to particle size of diluents.
The dominating bonding mechanism responsible for agglomerate formation was found to
be solid bridge formation between drug particles during compression. The API to API
particle agglomeration during compression was successfully prevented by using particle
agglomeration inhibitors (PAI’s). Treatment with hexane and increase in the level of
super disintegrant provided limited prevention of agglomeration during compression for
furosemide particles. The spray drying with either mannitol or hydroxy propyl starch for
micronized furosemide significantly reduced the agglomeration of API particles during
compression. Roller compaction process with Lutrol F68 micro and PEG 3350 provided
significant reduction in the agglomeration of drug particles for both the API’s during
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compression. Compression force and treatment with PAI’s on polymorphism was
observed in changing the crystal structure and polymorphism during compression and
confirmed by thermal and X-ray crystallographic studies for both the API’s. Scanning
Electron Microscopy studies revealed compression force and roller compaction process
with PAI’s changed the surface morphology of both the API’s.
The results of the above studies indicated that compression of micronized
hydrophobic poorly soluble drugs into tablets affects the dissolution rate due to
agglomeration of API. The micronization process for improving the dissolution rate of
poorly soluble drugs showed disadvantageous with respect to tablets compressed at high
compression forces because of agglomeration of furosemide and griseofulvin particles
during compression. Hence control of particle size and selection of size of diluents are
necessary during formulation of tablets of hydrophobic poorly soluble drugs. Primary
particle size increase of micronized hydrophobic drugs during compression can also be
minimized by treatment with particle agglomeration inhibitors prior to compression.
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CHAPTER 1.

INTRODUCTION

Poor aqueous solubility and poor oral bioavailability of drugs are the two most
discussed topics in the published pharmaceutical research. Most of the new chemical
entities synthesized currently through traditional combinatorial chemistry or through
analogous synthesis schemes are hydrophobic in nature and are difficult to dissolve in
aqueous solutions. The desired pharmacological response for administered drug can be
manifested only when it is available in sufficient concentration at receptors.1 At present
40% of the new chemical entities in the developmental pipeline are poorly soluble, and
even up to 60% of the compounds coming directly from synthesis are poorly soluble.2-5
Some diseases need chronic drug treatment and other diseases need acute or short term
drug therapy. Chronic drug therapy or extended drug treatment can be achieved by
modifying drug release characteristics from dosage forms. For acute drug therapy, most
of the patients prefer injections, solutions or immediate release solid dosage forms. The
oral route is generally the preferred route of drug administration where possible, due to
patient compliance, convenience and lower production costs. For any drug to be absorbed
into systemic circulation after oral administration that drug should dissolve in the gastric
fluids.6 For better therapeutic response the drug must be in molecular dispersion form that
means a true solution at absorption site. According to Biopharmaceutical Classification
System the drug dissolution and gastrointestinal permeability are the fundamental
parameters controlling the bioavailability of drugs.7 Absorption of drugs through the
intestine is purely depends on their physicochemical properties like molecular weight,
pKa, logP, solubility, intrinsic dissolution rate, polymorphic nature of drug, particle size,
pH environment of gastro intestinal tract and its content. Based on the aqueous solubility
and intestinal permeability the biopharmaceutical classification system classified the
drugs into four categories. For any drug substance classified as highly soluble in BCS
class I and class III category its highest dose should be soluble in 250 ml or less aqueous
medium at pH range of 1.0-7.5.8 Dissolution of a drug in the gastrointestinal fluids is
often the rate limiting step for oral bioavailability. According to Noyes-Whitney in
Equation 1-1.9
−

=

ℎ

(Eq. 1-1)

Where dw/dt is the rate of dissolution of a drug, D is the diffusion coefficient of a
drug, A is the surface area of a drug accessible to dissolution media, Cs is the
concentration of a drug surrounding layer of a solid, C is the concentration a drug in the
bulk dissolution media which is negligible compared to Cs10, h is the thickness of a
diffusion layer. In the above Equation 1-1, the diffusion coefficient D is depends on the
viscosity of gastrointestinal fluid and/or its contents and the thickness of a diffusion layer
h depends on the hydrodynamics during gastrointestinal transit.11 These latter two
parameters have less impact as a target to improve the dissolution rate of poorly soluble
drugs. The other two terms in the Equation 1-1 can be used to improve bioavailability by
increasing the surface area and by increasing the saturation solubility. Several literature
sources discussed saturation solubility increasing with decrease in particle size.12-14
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Dissolution rate increase can be achieved by reducing the particle size of the drug
and optimizing the wetting characteristics of compound surface to decrease the diffusion
layer thickness and by increasing the apparent solubility of a drug.15 Christer. N et al.,
studied the milled griseofulvin and found that the increase in solubility was due to
increase in surface free energy and reduction in heat of fusion and disordering of solid
structure.16 Currently; there are numerous techniques available to increase the dissolution
rate by particle size reduction to micro and nano size,17-20 by forming solid
dispersions,21,22 by forming inclusion complexes with cyclodextrins23,24 and by forming
salts.25 Increase in dissolution rate of poorly soluble drugs by micronization is a wellknown topic.26 For some drugs, like griseofulvin the degree of alimentary absorption and
increase in blood concentration is directly proportional to particle size.27 Instability of
solid dispersion systems28 and the size of the molecule and its conformational fit for
inclusion complexation with cyclodextrin ring are some of the disadvantages.29 Among
these techniques the size reduction to micron or nano size is one of the suitable
techniques to get successful enhancement of dissolution rate for poorly soluble drugs.30
Currently marketed and under development technologies for poorly water soluble drug
substance are presented in Table 1-1.31
1.1

Micronized Powder Properties

Knowledge about micronized or nano sized powder properties is very important
in the pharmaceutical industry. The major and important properties of micronized
powders are 1) individual particle shape and surface area, 2) particle size distribution and
total surface area. As the dissolution rate of poorly soluble drugs increases with
decreasing the particle size, the estimation of particle size is an important material
characterization parameter in the drug development stage. Generally the particle size is
expressed in microns (µm, micrometer) or nanometer (nm). But for dissolution generally
must be related to surface area. The most critical part of particle size analysis is method
development and validation. There are several methods in practice across the industry for
estimation of particle size. Some practical issues to be considered in estimation particle
size, in dry method the particles could be exposed to significant stress as this method uses
heavy air streams. Whereas in wet analysis, the material should not be soluble in the
dispersant and it should compatible with the wetting agent used in the media. The impact
of shear due to sonication during measurement should be evaluated so that the particles
should not be fractured.
The micron (10-6) or nano (10-9) size particles are very small in size; their surface
area will be large because of generation of new surfaces during micronization process.
This increase in surface area is responsible for hastening the dissolution rate of poorly
soluble drugs. Surface area of powders can be measured normally by Brünauer-EmmettTeller or B.E.T method and expressed as specific surface area.
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Table 1-1.

Marketed approaches to solubility enhancement of poorly water- soluble drug substances
Particle size

Method

Process

Technology

Owner

Marketed products

Micron (nano particle)

Down-sizing

Milling

Nanocrystal

Elan

Rapamune®,
Emend®

Down-sizing

Homogenation

IDD

SkyePharma

Triglide™

Down-sizing

Homogenation

Nanopure

PharmaSol

Under development

Down-sizing

Homogenation

Nanoedge

Baxter

Under development

Down-sizing

SCF

SCF milling

DuPont

Under development

Build-up

SCF

SFEE

Ferro Corp

Under development

Build-up

SCF

SAS-EM™

Thar Tech

Under development
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1.2

Mixing of Micronized Powders

Mixing of micronized powders along with other excipients in drug development is
a crucial and cumbersome process. Two types of mixing exist to get good blend
homogeneity in solid dosage form development. They are 1) ordered mixing, 2) random
mixing. The mixing process is represented in Figure 1-1. Ordered mixture is formed by
mixing fine cohesive powders and coarse free flowing powders. Adsorption of fine
particles on coarse particles determines the homogeneity of the blend. For any random
mixture the particles in the blend need not to be in different size, but the content of the
sample taken from the random mixture at any place in the mixture should be same.32,33
Particle segregation and agglomeration are the two major problems that could arise
during blending of different size powders. With some limitations the ordered mixing
process reduces the segregation. This segregation and agglomeration can be minimized
by modifying the particle size and the shape of the drug particles.34 Type and extent of
particle adsorption can be shown to be dependent on the size and physicochemical
properties of the particles. For some drugs like antibiotics adsorbs more on sorbitol
instant pharma compared to crystalline sorbitol due to its high adsorption capacity and
binding strength.35 For micronized cohesive hydrophobic drugs like griseofulvin the
ordered mixing process by mixing with sodium chloride as diluent increased the contact
surface area exposed to dissolution media.36 Hydrophobic diluents such as di calcium
phosphate dihydrate gave limited increase in the dissolution rate of griseofulvin suggests
that use of a soluble diluent is preferred. The higher degree of surface coverage by drug
particles on carriers by ordered mixing increased the dissolution rate of griseofulvin
blend as well as tablets. This effect was altered by increasing the drug loading and also
due to formation of drug film on carrier particles which blocks instantaneous dissolution
of the latter.37,38
1.3

Compaction of Micronized Powders

Particle size importance during compaction of powders was studied over the
years.39-41 Eighty per cent of the human use and marketed dosage forms are tablets.42
Tablets are the most patient compliant, suitable for large scale production and cost
effective unit dosage forms in the market. All tablets should possess adequate mechanical
strength to with stand processing and transportation and deliver the drug in a
predetermined pattern.
The effect of compression force on particle size distribution will provide
information about the particles morphology. During the tableting process, the massive
compression force applied to the powder bed induces considerable deformation in the
solid particles. The expected data from these compression studies should provide whether
the particles undergoing any morphological changes during compression like formation
of large crystals or aggregates by melting or formation of high energy fine solid particles
by fragmentation. For most of the pharmaceutical blends these forces are large enough to
exceed elastic limit of the solid that lead to breakage of particles by fracture.
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Figure 1-1.

Powder mixing patterns
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1.3.1

Stages of compression

When an external force is applied uniaxially on a powder bed in a die its volume
reduces and its interparticulate porosity decreases. The term compressibility is defined as
the ability of a powder material to reduce its volume under pressure, whereas the
compactability is the ability of a material to form a solid compact with specific
mechanical strength.43 Stages of powder compression are presented in Figure 1-2.44
An external force applied on a powder bed initially forces the small particles in
the powder blend to rearrange by sliding and fill the voids between the particles. Upon
further increasing the force there will be a friction between particles that prevents further
relative movement of the particles inside the die and powder forced to transform into a
denser solid compact. At this stage the powder particles at contact points feel stress and
start to deform. If the deformed powder particles regain their original shape upon removal
of the force then it is called elastic deformation which is a reversible process. If this
deformation is irreversible that is called as plastic deformation. For most of the plastically
deformed materials fragmentation occurs further and they break into smaller particles
upon increase in applied force. These small particles with new surface increase the
compact strength by forming interparticulate bonding due their high surface area and
surface energy. In summary one single particle undergo several of these processes during
compression and with the other materials can form a coherent compact with the welldefined shape of a tablet. As the compression force increases the specific surface area of
the particles increases proportionately to some extent and then reduction in the specific
surface area is observed due to agglomeration of fragmented particles. The sequences of
events occur during tablet compaction process are: a) particle rearrangement, b) elastic
deformation, c) plastic deformation, d) particle fragmentation, e) formation of
interparticulate bonds.39,45,46
1.3.2 Particle bonding and bonding mechanism
The two important factors for compactability of powders are the dominating bond
mechanism and the surface distance over which these bonds are active.47 The volume
reduction during compression is an endothermic process that normally requires more
energy to form a compact with high surface area by interparticulate attraction forces.
Particle bonding during compression is an exothermal process that releases energy.48
Most of the pharmaceutical materials possess poor thermal conductivity and low specific
heat. Increase in mechanical strength of a compact by particle/ particle interaction can be
defined as consolidation. A number of mechanisms have been proposed for
interparticulate bonding during compression a) solid bridges caused by melting and
subsequent cooling, b) mechanical interlocking between irregularly shaped particles, c)
attractive forces like coulomb forces between charged particles, d) covalent bonds, e)
hydrogen bonds and f) van der Waals forces.49,50 For simplicity the dominating bonding
mechanisms can be limited to three: 1) solid bridges, 2) distance attraction forces, 3)
mechanical interlocking.51 Some specifications of bonding mechanisms in compacted dry
powders are presented in Table 1-2.47

6

Figure 1-2.

Stages of compression

Modified with permission: Marshall K. 1986. Compression and consolidation of
powdered solids. In Leon Lachman HAL, Joseph L. Kanig, editor The Theory and
practice of Industrial Pharmacy, 3 ed., Philadelphia: Lea and Febiger. p 66-99.
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Table 1-2.

Some specifications of bonding mechanisms in compacted powders

Type
(bonding)

Dissociation energy
(kcal/mol)

Separation distance
at equilibrium
(Å)

Maximum
attraction
distance (Å)

<2

Solid bridges
Covalent
homopolar

50-150

<2

Covalent
heteropolar

100-200

<2

Ionic

100-200

<3

Hydrogen bonding

2-7

3-4

van der Waals

1-10

3-4

< 10

Inter molecular forces

100-1000

Electrostatic
Mechanical
interlocking

Variable depends on the shape, bulkiness and flakiness of the
particles

Å: Angstroms
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During the compression process the particles in direct contact with the upper and
lower punch surfaces undergo a pressure effect. Inside the powder bed the particles
undergo stress due to particle-to-particle contact. The area at which particle-particle in
contact is very small and pressure exerted at contact points can be extremely high. This
can raise the temperature and melt the powder particles during compression. For surface
fusion there should be formation of localized high temperature hotspots. If the
temperature of these hotspots reaches the melting point of the substance being
compressed, the surface fusion can occur.52For some pharmaceutical mixtures the
excipients could lower the melting point of pure drug during compression, so the surface
fusion could occur before reaching the melting point of drug. For some drugs like
phenylbutazone and chloropropamide polymorphism could occur during compression and
suggests that this mechanochemical effect is due to melting of drug during
compression.53
1.3.3

Evaluation of bonding mechanism

Various bonding mechanisms are involved in the consolidation of powder
particles during compression but still it is not clear which bond is dominating in the
formation of solid compact with strong mechanical strength. Tensile strength of the
compact is the best parameter to assess the dominating bonding acting between the inter
particulates. Out of three dominating bonding mechanisms, mechanical interlocking
which is twisting or hooking together normally occurs in the particles with elongated and
/or irregular in shape.51The above mechanism happens most of the time in compression of
metals. The solid bridge formations are assumed to be strong bond formation due to close
contact between particles. Whereas the attraction forces between particles are weak and
act at a short distance. When the distance between the powder particles reduced to 1001000 Å the weak long range distance forces, i.e. van der Waals forces, hydrogen bonds
and electrostatic attraction forces are likely to occur.54
Evaluation of the dominating bonding mechanism responsible for formation of
compact was studied by measuring electrical conductance in the compact under pressure,
and also by using magnesium stearate as barrier against distance forces between
particles.55,56 However, most of the pharmaceutical materials are poor conductors of
electricity which is prerequisite for conductance. Luangtana-anan et al., described an
alternative method to differentiate weak long range distance forces and solid bridge
formation during compression. In this method tensile strengths of the compacts were
evaluated after soaking the compacts in various liquids with a different dielectric
constant. Decrease in the tensile strength results in the weak compacts with increasing
dielectric constant of the solvent and reaches to plateau at a dielectric constant of
between 10 and 20.49,57-59 Van der Waals forces act between most of the particles and it
also depends on the properties of the particles and their surrounding medium. In air these
bonds dominate in adhesion of the particles. According to Equation 1-2, the energy (W)
between two surfaces is directly proportional to the Hamaker constant (A) and indirectly
proportional to distance between surfaces (d).
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(Eq. 1-2)

The interactive forces between surfaces can be expressed as Equation 1-3.
/

= 24

2

/

(Eq. 1-3)
In which γs/l, is surface energy of particles between two phases of solid and liquid
medium. The surface energy of a particle is affected by dielectric constant. A high
dielectric constant results in the lower surface energy and thus reduction in the strength of
the van der Waals forces.
1.4

Agglomeration of Micronized Powders

Even though the micronization process offers advantages among other techniques,
it has some limitations as it generates dust, the materials possess poor flow properties
which create formulation processing problems.60 Due to very small size, and these
micronized powders exhibit cohesive and adhesive properties, this result in the formation
of agglomerates. These agglomerates may break easily if they formed by weak forces but
these may affect the disintegration and dissolution if they are strong. Formation of
agglomerates depends on the initial particle size, generally elastic modulus and
interparticulate bond strength. Agglomeration of particles is due to inter particulate
bonding by weak van der Waals forces.61 Strongly agglomerated micronized drugs may
not show any improvement in dissolution rate as the exposed external surface area of
primary particles to the media is substantially smaller. This shows the disadvantageous
effect of micronization. To improve the liquid penetration into the agglomerates and thus
to increase the surface area contact use of surfactants are desirable.62-64
1.5

Particle Agglomeration Inhibitors (PAIs)

Particle agglomeration inhibitors (PAIs) are the agents that prevent the
aggregation of API-API particles during compression and also separate the hydrophobic
API particles from diluents when in contact with aqueous environment by changing
surface properties like increase in wetting and decrease in surface free energy. When
micronized hydrophobic API powders were formed into a large solid coherent compacts
like tablets their disintegration and dissolution will be decreased due to agglomeration
and aggregation. By treating the hydrophobic API with particle separating agent and
incorporating that treated particles into a tablet results in improving dissolution rate. The
ratio of drug to particle separating agent adjusted to 1:20 to about 20:1.65The PAI’s
should be hydrophilic in nature with low melting point and should also possess good
compressible characteristics with high surface area.
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1.5.1

Disintegrating agents

Particle agglomeration can be resolved by adding an excess amount of
disintegrating agents or combination of agents such as sodium starch glycolate,
croscarmellose sodium. As per literature more than 10 % of disintegrating agent can be
used for poorly water soluble drug substances to get a desirable dissolution profile.
Increase in disintegrant concentration also increases the weight of the tablet. Most
disintegrating agents possess capillary and wicking properties for swelling and
disintegration of tablets. Some dosage forms show differences in their disintegration and
dissolution behavior during shelf life studies due to moisture pick-up by large quantities
of disintegrating agents. Sometimes the disintegration process could slow down due to
surface coating of disintegrants by micronized hydrophobic API particles or by
magnesium stearate.66Some of the more common super disintegrating agents available in
the market are Crospovidone (Poly Plasdone®XL-10), croscarmellose sodium (Ac-DiSol®), and sodium starch glycolate (Explotab®). Among these super disintegrants
croscarmellose sodium improved the disintegration properties from its capillary and
swelling properties when used in dry granulation process. A very small percentage (0.1
to 1.0) of croscarmellose sodium was used in this thesis because of its insoluble nature in
water.
1.5.2

Surfactants

Surfactants are agents with hydrophilic and lipophilic groups attached together as
head and tail respectively and these surfactants decrease the surface tension between two
liquids or between liquid and solid surfaces. Surfactants or wetting agents can be used as
particle agglomeration inhibitors. Block co polymers like Lutrol F 68 micronized powder
with large surface area can be used as a PAI. The chemical structure of Lutrol F68 is
presented in Figure 1-3. The melting point of Lutrol F 68 micro is 52-57°C. Polyethylene
glycols are non ionic substances and can be used as a wetting agent as well as surfactants
in preventing particle agglomeration during compression due its low melting and
lubricating properties. They also used as lubricants and binders in tablets. The chemical
structure of polyethylene glycol is presented in Figure 1-4.Granular PEG 3350 with high
surface area and low melting point of 54-58°C can be used as PAI. The most important
property of PEGs is their solubility in water.
1.5.3 Starches
Starch is one of the naturally existing material and best disintegrating agents used
in the most tablet formulations. Currently in the market partially gelatinized maize starch
(Starch 1500®) is available as a binder, disintegrant, flow aid and self-lubricant. Hydroxy
propyl starches are hydrophilic and also aid in swelling and dissolution properties of
starches. Hydroxy propyl starches are suitable for forming highly transparent films.67
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Figure 1-3.

Lutrol F®68

Figure 1-4.

Polyethylene glycol
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Dry powder coating consists of spraying a fine powder and plasticizer on
particles.68Currently, a hydroxyl propyl starch polymer READILYCOAT™ is using as an
aqueous film coating material for tablets due to its excellent water solubility and
rheological properties.
1.6

Spray Drying

Spray drying is a process of quench cooling of solution or suspension by
atomization through heated air in a drying chamber. Mixing with hot air the atomizer
produces small droplets and then rapid evaporation of solvents takes place. The hot air
can be same direction or counter-flow. Finally, the formed small fine particles are
collected from a cyclone that separates solid particles from hot air.69
Co-processing by spray drying for excipients having superior properties compared
to individual excipients or their physical mixtures is commonly done. This process gives
several advantages like improvement of density, flow, porosity and compactability.
Surface energy of materials can be modified by keeping powder bulk properties like solid
state and compatibility by spraying drying along with surfactants.70 Spray drying of drug
substance along with excipients is an alternative method to improve the content
uniformity and adsorption of fine cohesive particles on coarse excipients.
1.7

Roller Compaction

Dry granulation is one of the granulation processing methods presently most of
the industry showing interest due to availability of directly compressible excipients. Still
less than 20 percent of API’s are not directly compressible due their high dose, poor flow,
poor lubrication or highly cohesive properties.
Even with significant disadvantages such as poor tensile strength for tablets
produced from roller compacted granules and a relatively expensive process, formulators
and industry often prefer the roller compaction process due to its efficient production
output, continuous process and less labor intensive operations. The main advantages of
the roller compaction process are: 1) increase in bulk density, 2) increase in drug
homogeneity by decreasing segregation, 3) increase in disintegration time, and 4)
increase in flow of granules by increasing the size of the granules. However, for high
drug loading formulations a wet granulation process is often the only practical method.71
1.8

Objectives

The main objective was to estimate the API particle size distribution after
compression into tablets of a micronized API. Specific aims included•

To estimate the effect of compression force on API to API particle agglomeration
during compression
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•
•
•

To estimate the effect of amount of API content on API to API particle
agglomeration during compression
To evaluate the bonding mechanism responsible for agglomeration of API to API
during compression
To prevent the API to API agglomeration during compression by various
treatment and processing methods

Based on the Biopharmaceutical Classification System (BCS) two model drugs
were selected. BCS class II (poorly soluble and highly permeable) drug griseofulvin and
BCS class IV (poorly soluble and poorly permeable) drug furosemide were selected.
1.8.1

Furosemide

Chemically furosemide is 5-(aminosulfonyl)-4-chloro-2[(2-furanylmethyl) amino]
benzoic acid with a molecular weight of 330.7. Furosemide is light yellowish crystalline
powder and it is practically insoluble in water with 206°C as melting point. In studies of
dissolution rate improvement for furosemide, seven polymorphs were reported, but four
of them were found to be true polymorphs. There were also two solvates (DMS and
Dioxane) and one amorphous form.72-76There were no reports of polymorph dependant
bioavailability of furosemide. Furosemide aqueous solubility at room temperature was
reported to be as 0.01825 mg/ml at room temperature.77 Furosemide is a weak acid with
3.8 as an acidic pKa value.78 Furosemide was the first high ceiling loop diuretic drug and
to also be used as an antihypertensive. Furosemide USP (marketed as Lasix®) is
available in 20, 40 and 80 mg tablets. Furosemide oral solution and its sodium salt as
parenteral injection formulations and aerosol formulations are also available in the
market. Oral bioavailability of furosemide was reported as approximately 60 % with an
elimination half life of 1.5 hrs and a renal elimination of 65 % as intact drug. Furosemide
we used in this dissertation was micronized one with mean particle size of around 5
micron and its structure is presented in Figure 1-5.
1.8.2 Griseofulvin
Griseofulvin is an antifungal antibiotic discovered in 1959. Chemically
griseofulvin is (2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[1-benzofuran2,1'-cyclohexan]-2'-ene-3,4'-dione and its molecular weight is 352.77 and its structure is
presented in Figure 1-6. It is a white crystalline octahedra and rhombus shape with
219°C as melting point. Griseofulvin was classified as a BCS class II category due to its
poor solubility and high intestinal permeability. The aqueous solubility of griseofulvin
was reported to be 0.03056 mg/ml and log P value of 2.18. Due to its high variability
through oral absorption, griseofulvin is often used as a model drug for any solubility
improvement, dissolution improvement, bioavailability improvement and novel dosage
forms like SMEDDS/SEDDS.80 Griseofulvin is available in micro size and ultra micro
size as tablets. GRIS® PEG 125 mg tablets are available as PEG solid dispersion dosage
form. In humans this product showed variability when administered with and without
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Figure 1-5.

Furosemide chemical structure

Figure 1-6.

Griseofulvin chemical structure
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food. Griseofulvin USP available in tablets, capsules, suspensions, powders. Oral
absorption of griseofulvin was greater with foods containing fatty acids. Oral absorption
of micro size griseofulvin formulations was variable (20-75 %) whereas ultramicrosize
showed 100 % absorption when administered orally. The elimination half-life of
griseofulvin found to be 24 hrs. By ultra micronization process the oral dose of 500 mg
was reduced to 250 mg and proved to be bioequivalent with single 250 mg dose.81,82
The particle size of griseofulvin we used in this disseration was around 13 micron in size.
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CHAPTER 2. COMPRESSION FORCE INFLUENCE ON DRUG-DRUG
PARTICLE AGGLOMERATION DURING TABLETING OF MICRONIZED
API
2.1

Introduction

Disintegration of tablet followed by dissolution of primary particles of it and
absorption of dissolved drug, all these events occur in a sequence after oral
administration.83 According to Noyes- Whitney equation the dissolution rate is directly
proportional to surface area of dissolving drug particles, solubility of the drug in the
solvent and indirectly proportional to thickness of the diffusion layer surrounding the
solid particles.9 For increasing the dissolution rate of hydrophobic drugs, particle size
reduction to micron or nano size is a common practice. This size reduction increases the
surface area of the drug particles thereby increasing the dissolution rate. Size reduction is
a potential advantage. However, compressing micronized drug particles i.e., bringing all
these micronized drug particles together along with excipients to form a solid tablet could
generate some reduction in its potential advantage. Compared to specific surface area of
the drug particles, the effective surface area of the drug that is exposed to gastrointestinal
fluids in a dosage form after disintegration is the most important factor to be taken into
consideration in development of dosage form.84
However, micronization of API for increasing the surface area thereby increasing
dissolution rate may not be adequate if the drug undergo agglomeration due to bonding
during compression into tablets. When micronized hydrophobic drug powders are diluted
with various tableting ingredients and compressed into tablets, the primary particle size
of the micronized drug powder can increase significantly during compression. However,
to evaluate this effect an intact tablet dissolution does not provide information on what is
happening to the API particle size during compression of tablets.85
Carless et al. described as coarser particles undergo fragmentation during
compression and fill the voids whereas finer particles during compression cannot break
further due to their dimensions and hence fuse together. At high compression forces fine
particles of size less than 100 microns experience high degree of shear on their surface
and at contact points. This results in the local melting of the surfaces below its melting
points. Upon releasing the compression force from the powder bed the aspertically
molten surfaces solidify and forms sold bridge between particles. A larger surface area of
micronized API particles provides a larger number of contact points and hence bonding
between the drug particles may occur during compression. As the particle size decreases
the tensile strength of the tablets increases; this is due to strong bonding between fine
particles.86 Higuchi et al. described as the compression pressure increases specific surface
area initially increases and then decreases.87 Due to variation in the distribution of
pressure during compression inside the die the resulting compact will be
nonhomogeneous. Also defects on the crystal surface or disorders in the lattice due to
compaction are known to give rise to structure-sensitive diffusion of the solvent used.88-90
Mikko et al. studied the crystal defects during compression for tolbutamide and
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chloropropamide tablets that affects the dissolution rate by grazing incidence x-ray
diffraction method.91 This increase can significantly alter the dissolution rate of the drug
and reduce the absorption for certain drugs.
Khan et al. studied the effect of compaction on particle size of different type of
materials (brittle materials, deforming materials and ductile materials with low melting
point) and found considerably different particle size after disintegration.92 As compaction
pressure increases the dissolution rate also increases due to fragmentation of drug
particles within in the compact.93 However, Hirshorn et al. found a decrease in drug
dissolution rate by increasing the compaction force and this could be due to changes in
surface area of drug particles after compression and that it also depends on the dilution of
drug particles with additives.94 In this chapter, the effect of drug loading and compression
force on micronized furosemide and griseofulvin API were studied.
Tuladhar et al. described the change in the API particle size during compression
was affected by nature of the diluents present in the formulation and also found that the
agglomeration of fine particles during compression was independent of rate
compression.95 Highly homogenous blend for highly cohesive micronized API can be
achieved by blending the formulation with highly porous and freely flowing diluents.
However, some diluents with highly indented surface may entrap the micronized drug
and forms pockets of agglomerates which hamper the dissolution.96,97 Effect of particle
size of diluent (lactose, di calcium phosphate dihydrate) on micronized API
agglomeration during compression were investigated and results were discussed in this
chapter.
Changes in the particle size of API during compression might be due to several
mechanisms. Solid bridge formation, weak long range forces and mechanical interlocking
are the probable mechanisms for compact formation. The strongest bond among the
probable mechanism in bond formation, Solid bridges, described as areas in which
particles are partially fused during compression by formation of continuous phase
between two particles. It is very difficult to define the area responsible for agglomeration
of particles during compression if the particles undergo weak long range forces.47,98,99
Evaluation of mechanism responsible for agglomeration during compression can be done
by filtering out weak long range distance forces. Luangtana-anan and Fell described the
evaluation of bonding mechanism method by measuring the tensile strength of compacts
after soaking in various liquids with different dielectric constants. The assumption was
that increase in dielectric constant liquid media should decrease the tensile strength of the
compacts if there is any weak long range distance forces are acting between the particles
during soaking.49
The objective of the present study was to investigate the effect of compression
force, drug loading and effect of diluent particle size on micronized API’s: Furosemide
and griseofulvin. Particle size distribution, dissolution and characterization of particles by
differential scanning calorimetry powder x-ray diffraction and scanning electron
microscopy studies were performed. The dominating bond responsible for agglomeration
of micronized griseofulvin during compression was evaluated.

18

2.2

Materials and Methods

2.2.1 Materials
Furosemide (micronized API) was purchased from Teva Pharmaceuticals, Israel.
Micronized griseofulvin was a generous gift from Wuhan Yuancheng Technology, China.
Modified spray dried lactose 315 (Foremost® NF Lactose) was purchased from Foremost
Forms, Baraboo, WI. Di calcium phosphate di-hydrate (Di-Tab®) was purchased from
Rhodia, Inc, Cranbury, NJ. Croscarmellose sodium (Ac-Di-Sol®) was obtained from
FMC biopolymer, Philadelphia. Magnesium stearate NF was purchased from
Mallinckrodt, St. Louis, MO. Pure n-butanol, ethanol and n-hexane were purchased from
Sigma Aldrich, St. Louis, MO. ACS grade Acetic acid glacial was purchased from EMD
chemicals, Billerica, MA. Sodium dodecyl sulfate and sodium acetate were purchased
from Sigma Aldrich, St. Louis, MO.
2.2.2 Methods
2.2.2.1

Determination of equilibrium solubility studies

Furosemide and griseofulvin were separately added slowly in excess amount to
stirring water and continued stirring in a shaker bath for 24 hours at 37°C temperature to
achieve equilibrium solubility. Samples in triplicate were withdrawn and filtered using
25mm PVDF 0.45 µm syringe filter (Millipore Millex) and diluted with water. The
diluted samples were assayed for furosemide and griseofulvin by UV-Visible
spectroscopy at 272 nm and 295 nm respectively. The same procedure was also repeated
in acetate buffer USP (pH 4.5) for furosemide.
2.2.2.2

Preparation of saturated solutions

Saturated drug solution of furosemide and griseofulvin were prepared by adding
excess amount of drug in distilled water with 0.1 % Tween-80 as a wetting agent and
stirred for 12 hrs and vacuum filtered through 0.45 µm membrane filter. This saturated
drug solution was used as a medium for disintegration of tablets and for the measurement
of particle size by suspension method using light scattering technology.
For diluent particle size effect study a saturated furosemide solution was prepared
in 0.1N hydrochloric acid. This saturated solution was used for disintegration of tablets
containing DiTab as diluent to dissolve dicalcium phosphate dihydrate during
disintegration.
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2.2.2.3

Preparation of blends

Furosemide and griseofulvin were accurately weighed according to formulation in
Tables 2-1 and 2-2. Initially API’s and spray dried lactose were mixed together by
geometric mixing by passing through #60 stainless steel mesh twice and finally Ac-DiSol was blended in a plastic bag for 5 min.
2.2.2.4

Effect of diluent particle size

Two diluents were selected for this study. Manufactured supplied spray dried
lactose (Foremost Lactose 315 NF) and dicalcium phosphate dihydrate (DiTab) was
fractioned into two fractions by sifting through stainless steel mesh #60 (250 µm), #80
(180 µm) and #200 (75 µm). Particles from both the diluents under 75 µm were collected
and named as fraction-1 and particles under 250 µm and above 180 µm were also
collected and named as fraction-2. Micronized furosemide was used as a model drug for
this study. Micronized furosemide and above fractions were accurately weighed
according to Table 2-3 and geometrically mixed by passing through #60 mesh twice and
blended with Ac-Di-sol for 5 minutes.
2.2.2.4.1

Estimation of diluents particle size

The mean particle sizes of above fractions were confirmed by laser diffraction
technique using a Digisizer (Saturn Digisizer® 5200, Micromeritics). Iso propyl alcohol
and water were used as a suspending media for measuring particle size of lactose and
DiTab respectively. A saturated solution of lactose in isopropyl alcohol and dicalcium
phosphate dehydrate (DiTab) in water were prepared by adding excess amounts into these
solvents and stirred overnight and vacuum filtered.
2.2.2.4.2

Estimation of diluents specific surface area

The specific surface area of above fractions was estimated using gas adsorption
technique by Micromeritics Gemini 2360 surface area analyzer. The sample tubes
containing sample were dried under stream of N2 gas at 60°C using Flowprep 060
(Micromeritics). The specific surface area was calculated using multi point BET
equation.
2.2.2.5

Compression of tablets

Tablets of weight 200 mg for furosemide and 400 mg for griseofulvin were
compressed on a hydraulic manual bench top laboratory press (Model C, Carver, Inc)
with dual scale gauge. 5/16” FFBE (flat face bevel edge) for furosemide and 3/8” FF (flat
face) for griseofulvin tooling were used with 7.93 mm and 9.5 mm diameter dies
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Table 2-1.
study

Formulations for furosemide compression force and drug loading
Formula
Furosemide (%)
Spray dried lactose (%)
Ac-Di-Sol (%)
Total (%)

Table 2-2.
study

F-2
20.00
79.90
0.10
100.00

F-3
30.00
69.90
0.10
100.00

Formulations for griseofulvin compression force and drug loading
Formula
Griseofulvin (%)
Spray dried lactose (%)
Ac-Di-Sol (%)
Total (%)

Table 2-3.

F-1
10.00
89.90
0.10
100.00

G-1
15.00
84.90
0.10
100.00

G-2
30.00
69.90
0.10
100.00

G-3
60.00
39.90
0.10
100.00

Formulation for diluent particle size effect study
Formula
Furosemide (%)
Spray dried lactose (%)
DiTab (%)
Ac-Di-Sol (%)
Total (%)

D-1
30.00
69.90
0.10
100.00
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D-2
30.00
69.90
0.10
100.00

respectively. Magnesium stearate was applied to surface of both punches before
compression and 3 sec dwell time was maintained for all the compression forces. Four
compression forces 0.5 mT, 1.0 mT, 1.5 mT and 2.0 mT were studied. Six tablets were
compressed for each compression force and each percent drug loading.
For diluents particle size effect study furosemide tablets of 200 mg weight from
each diluents blend were compressed at 2mT compression force using 5/16” FFBE
tooling. 3 sec dwell time was also maintained.
2.2.2.6

Disintegration of tablets

Disintegration of tablets was done in QC-21™ (Hanson research) disintegration
test system in saturated drug solution at room temperature. After disintegration of all six
tablets process was further continued for another one more hour to dissolve all soluble
excipients in the media. The residue was collected by vacuum filtration. The dried
residue was assayed for API and further for particle size measurement and particle
characterization and dissolution studies. For the diluents particle size effect study the
tablets were also disintegrated as described above.
2.2.2.7

Validation of disintegration process

Disintegration process was validated by measuring the API content in the residue
at different intervals of time. Six tablets at 2mT compression force with 30% drug
loading for each time interval were disintegrated and the residue was filtered at 0.5, 1.0
and 2 hr using vacuum filtration unit. A known quantity of residue was dissolved in
methanol and diluted further with methanol and absorbance was measured at λmax of 272
nm and 294 nm for furosemide and griseofulvin respectively.
2.2.2.8

Estimation of drug in the residue

The dried residue after filtration was analyzed for pure API’s (furosemide or
griseofulvin) after disintegration. To ensure all soluble diluents dissolved completely
after disintegration. A known quantity of residue was weighed in triplicate and dissolved
in methanol and filtered through syringe filter (Acrodisc CR PTFE 0.2 µm, 25 mm) and
diluted further with methanol. The absorbance was measured using UV/Vis
spectrophotometer (Lambda 20, Perkin Elmer) at λmax of 272 nm and 294 nm for
furosemide and griseofulvin respectively.
2.2.2.9

Measurement of particle size

A Saturn Digisizer® 5200, a high resolution laser particle size analyzer, was used
to measure the particle size of the residue from the disintegration study above. Saturated
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furosemide/griseofulvin solution was used as dispersion media to measure the particle
size. A suspension was prepared in saturated drug solution to measure the particle size of
the drug residue obtained after disintegration. A homogenous liquid-solid bubble free
suspension system was maintained by circulating the dispersed system at optimized speed
to get a concentration with appropriate obscuration of laser light. Figure 2-1 presents the
treatment of particles and tablets for particle size analysis and characterization.
2.2.2.10

Modulated differential scanning calorimetry

Modulated Differential Scanning Calorimetric (MDSC) studies were carried out
to confirm the polymorphic changes in furosemide or griseofulvin during processing and
tablet compression using a Q2000 DSC (TA instruments).MDSC studies were performed
with Q200 Differential Scanning Calorimeter (TA Instruments). Samples of
approximately 10 mg were heated in hermetic Tzero sealed aluminum pans. Melting
temperature (Tm) was measured under N2 atmosphere at flow rate of 50 mL/min. The
heating temperature range was from 25-220°C and ramping rate was 3°C/min and heating
modulation was 1°C/min. The data were analyzed using Universal Analysis software.
2.2.2.11

Scanning electron microscopy

Morphology of particles after compression was studied using an environmental
scanning electron microscope. Powder samples of furosemide and griseofulvin were
spread onto a double-sided adhesive carbon tape on an aluminum stub. Excess powder
was removed by gently tapping the stub. A thin coating (~ 25 nm) of gold was applied on
to the sample using a Hummer VII Sputtering System and observed under ESEM XL 30
(FEI). API powder samples and samples after compression at 2 mT compression with
30 % drug loading were observed under SEM.
2.2.2.12

Powder X-ray diffraction

Powder X-ray diffraction studies were conducted on a X-ray Diffractomer
(Bruker D8 Advance XRD system). The data were collected in the continuous scan mode
using a step size of 0.04° (2θ). The scanned range was 4–40° (2θ). Furosemide and
griseofulvin particles before and after compression at 2mT compression force and 30%
drug loading were examined for any changes in crystallography.
2.2.2.13

Dissolution studies

Dissolution studies were conducted for both the API’s particles before and after
compression. A rate limiting acetate buffer at pH 4.5 medium was used for furosemide
particles dissolution and water containing 0.54 % SDS for griseofulvin. A bathless
dissolution system from Distek inc operated at 50 rpm paddle speed for furosemide, and
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Figure 2-1.

Scheme of particles and tablets treatment for characterization
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75 rpm for griseofulvin at 37°C temperature. 20 mg and 15 mg powder samples of
furosemide and griseofulvin before and after compression respectively were suspended in
5 ml of dissolution medium and dispensed into dissolution vessels quickly to wet the
hydrophobic particles. On line dissolution data was collected at each 5 min intervals from
an automated fibre optic multi channel probes with Indigo software from pION Inc. The
absorbance data for furosemide and griseofulvin were collected at λmax of 272 nm and
294 nm respectively.
2.2.2.14

Drug-drug bonding mechanism

2.2.2.14.1

Solubility studies of griseofulvin in organic solvents

Solubility studies were conducted by adding excess quantity of griseofulvin in
hexane, n-butanol and ethanol solvents and stirred overnight. Individual samples were
withdrawn and filtered through syringe filter (Acrodisc CR PTFE 0.2 µm, 25 mm) and
diluted. The concentration of griseofulvin in the organic solvents was measured by
UV/Vis spectrophotometer (Lambda 20, Perkin Elmer) at λmax of 294nm.
2.2.2.14.2

Measurement of tensile strength of compacts

Griseofulvin API alone was compressed into compacts using a hydraulic manual
bench top tablet press (Model C, Carver Inc) with width of 3 mm and 9.5 mm diameter
by using 3/8” flat face tooling. Tablets of griseofulvin were compacted at four different
forces 0.5, 1.0, 1.5 and 2.0 mT. The upper and lower punch faces were lubricated by
applying to magnesium stearate (suspension in ethanol) for each compact. For each
compression force five tablets were compressed and soaked for 24 hrs in a solvent media
pre saturated with griseofulvin. The soaked compacts were dried in desiccator for another
24 hrs before mesuring the tensile strength. For control the compacts were compressd in
air/vacuum in the same manner and stored for 24 hrs in dessicator and measured the
tensile strength. Solubility of drug in these solvents was also studied. Tensile strength (σ)
of the dried tablets were derived from the crushing strength (hardness), thickness and
diameter of the tablets according to Fell and Newton described in the Equation 2-1
=

2
106

(Eq. 2-1)

Where F is force required to break the tablet diametrically, D is diameter of the tablet and
T is thickness of the tablet. The scheme of bonding study is presented in Figure 2-2.
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Figure 2-2.

Scheme for API-API bonding study
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2.2.2.15

Data analysis

Mean particle size data for both the API’s were used for comparison to evaluate
the effect of compression force and effect of drug loading. Particle size data obtained
after compression at various compression forces and drug loadings were subjected to a
student t test and p-values were presented.
2.3
2.3.1

Results and Discussion

Particle size analysis and SEM characterization

In order to introduce the general process of evaluation, Figure 2-3(a) to (d)
present the particle size distribution of furosemide and griseofulvin before compression
and after compression at 2 mT at 30% drug loading. The particle a size of API’s used in
the studies was confirmed by measuring particle size by laser diffraction technique. The
particle size distribution was represented in volume frequency percent. The mean particle
size of furosemide and griseofulvin before compression was found to be 5.04 ± 0.5 and
13.96 ± 0.23 µm respectively. Size distribution curve for micronized furosemide showed
a bi-modal distribution whereas for griseofulvin the particle size distribution found to be
a unimodal distribution. Figure 2-4(a) to (d) shows the SEM images of micronized
furosemide and griseofulvin before and after compression and disintegration.
Figure 2-3(b) and (d) shows the particle size distribution of furosemide and
griseofulvin particles after compression. Micronized particles of furosemide formed large
agglomerates after compression into tablet at 2 mT at 30% drug loading which results in
shifting of its distribution to right side skew distribution in Figure 2-3(b). The
distribution of griseofulvin after compression was similar to initial particle size
distribution but the size of the particles was varied. SEM images of furosemide and
griseofulvin were also correlating with their respective distributions before and after
compression. Surface morphology of furosemide particles after compression was changed
to big large chunks due to formation of agglomerates during compression.
Furosemide API particles before compression shown in Figure 2-4(a) were
crystalline in structure and like polygonal, cubical and rod in shape. According to de
Villiers et al, the micronized crystal form influences the cohesive properties and that in
turn affects its powder properties like flow, wettability, size distribution and density.100
SEM images of initial particles of griseofulvin in Figure 2-4(c) show crystals and
pyramid and elongated rod like shapes. Figure 2-4(d) shows the change in crystals habit
of griseofulvin (acicular and bipyramidal to aggregated particles) during compression at
2mT force. Compression of hydrophobic micronized API’s along with other excipients at
high compression force of 2mT at 30% drug loading results in the formation of strong
agglomerates which thereby could alter the dissolution and disintegration process.
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Figure 2-3.

Particle size distribution of furosemide and griseofulvin API particles

a) Furosemide particles before compression
b) Furosemide particles after compression at 2mT with 30% drug loading
c) Griseofulvin particles before compression
d) Griseofulvin particles after compression at 2mT with 30% drug loading
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Figure 2-4.

SEM images of furosemide and griseofulvin API particles

a) Pure furosemide particles before compression
b) Furosemide particles after compression at 2mT with 30% drug loading
c) Pure griseofulvin particles before compression
d) Griseofulvin particles after compression at 2mT with 30% drug loading
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2.3.2 Validation of disintegration process and assay of filtered residue
The filtered residue after dissolution of the soluble excipients was evaluated for
furosemide and griseofulvin and was accepted as a viable sample if the assay was above
95% API. This was considered as representative of the process and we further proceeded
with that residue for characterization and particle size estimation. Validation results of
disintegration process for furosemide and griseofulvin tablets compressed at 2mT with
30% drug loading is presented in the Table 2-4. The assay of furosemide after
disintegration at time intervals of 0.5, 1.0 hr were 95.67, 99.01 respectively. As the
disintegration time increases the soluble excipients inside the tablets undergoing
complete dissolution results in the assay of 99.06% after 2 hrs. Similarly the griseofulvin
tablet disintegration process was validated and the assay after disintegration at time
intervals 0.5, 1.0 and 2.0 hrs were 92.10, 95.70 and 99.73 % respectively.
2.3.3 Effect of compression force and drug loading
Figures 2-5 and 2-6 represents the effect of compression force and drug loading
on micronized furosemide and griseofulvin particles. An increase in the particle size was
observed for both the API’s with increase in compression force and increase in drug
loading. There are several mechanisms responsible for increase in particle size of large
agglomerates of drug during compression. The micronized furosemide particles with
mean particle size of 5.04 ± 0.5 µm were increased to 14.16 ± 3.6 µm, 42.7 ± 4.1 µm,
39.99 ± 2.7 µm and 65.79 ± 2.8 µm with 10% drug loading at 0.5, 1.0, 1.5 and 2.0 mT
compression forces respectively. Similarly the micronized furosemide agglomerates into
12.29 ± 8.5 µm, 73.12 ± 7.9 µm, 84.24 ± 2.3 µm and 97.14 ± 15.3 µm with 20% drug
loading at 0.5, 1.0, 1.5 and 2.0 mT compression forces respectively. With increasing
drug loading to 30% the micronized furosemide particles formed large agglomerates of
mean particles sizes 35.85 ± 11.2 µm, 139.5 ± 6.8 µm, 144.65 ± 6.3 and 150.1 ± 17.8 µm
at 0.5, 1.0, 1.5 and 2.0 mT compression forces respectively. No significant difference was
observed among compression forces in agglomeration of particles at all the furosemide
drug levels (p>0.05) whereas a significant difference was observed in particle size
increase during compression compared for drug loadings at various compression forces
(p<0.05). Compared to starting furosemide particle size the drug loading and
compression force increased the particle size during compression.
The initial micronized griseofulvin particles with mean particle size of 13.96 ±
0.23 µm agglomerated to 30.36 ± 1.06 µm, 42.89 ±1.85 µm, 49.39 ± 0.88 µm and 50.35
± 1.15 µm with 15% drug loading at 0.5, 1.0, 1.5 and 2.0 mT compression forces
respectively. Likewise the micronized griseofulvin particles agglomerated together
during compression with 30% drug loading into sizes 32.41 ± 3.5 µm, 55.00 ± 7.2 µm,
93.37 ± 6.4 µm and 111.46 ± 5.7µm at 0.5, 1.0, 1.5 and 2.0 mT compression forces
respectively. Whereas at 60% drug loading the micronized griseofulvin formed larger
agglomerates with mean particle sizes 51.02 ± 8.1 µm, 81.22 ± 32.89 µm, 108.9 ± 5.1 µm
and 69.82 ± 16.96 µm at 0.5, 1.0, 1.5 and 2.0 mT compression forces respectively.
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Table 2-4.

Validation of disintegration process
Time (hr)

Furosemide (%)

Griseofulvin (%)

0.5

95.67

92.10

1.0

99.01

95.70

2.0

99.86

99.73
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Figure 2-5.

Effect of compression force and drug loading on furosemide particles
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Figure 2-6.

Effect of compression force and drug loading on griseofulvin particles
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Fracturing of the formed agglomerates at 2mT compression force might be one of
the responsible mechanisms for nonlinearity of agglomerate formation with compression
forces. Significant difference was observed among compression forces in agglomeration
of particles at 15% and 30% of griseofulvin drug levels (p<0.05) whereas at 60% drug
loading no significant difference was observed in particle size increase during
compression compared for drug loadings at various compression forces (p>0.05).
Compared to starting griseofulvin particle size the drug loading and compression force
increased the particle size during compression. The increase in micronized griseofulvin
particle size during compression may be attributed to solid bridge formation. The extent
of particle agglomeration and the size of agglomeration during compression increases
with increasing drug loading and compression force. The difference in the particle
agglomeration during compression by increasing the drug content might be due to
protection effect of lactose in lower drug content level and more interaction of drug-drug
particle in high levels of drug content.101 And also high surface energy and greater
surface area of micronized powders could also be a contributing factor in the formation of
agglomerates during compression.
2.3.4 Modulated differential scanning calorimetry
Figures 2-7 and 2-8 represents thermograms of furosemide and griseofulvin API
particles and after compression respectively. Figure 2-7 represents the sharp endothermic
peak at 208°C in reverse heat flow for furosemide before compression sample represents
the crystalline nature of it. After compression at 2mT with 30% drug loading the
furosemide did not change its solid state nature at high compression forces and showed
nearly similar endothermic peak at 210°C. In Figure 2-8, griseofulvin particles showed
similar endothermic peaks at 219°C before and after compression at 2mT with 30% drug
loading. This melting endotherm corresponds to the crystalline nature of griseofulvin.
Similarly griseofulvin did not undergo any polymorphic conversion at high compression
forces studied at 2mT compression force.
2.3.5

Powder X-ray diffraction studies

Figures 2-9 and 2-10 represents the difractograms of furosemide and griseofulvin
API particles before and after compression respectively. In Figure 2-9 micronized
furosemide before compression showed intense peaks at 5.89, 12.05, 18.01 and 24.65
degrees. This confirms the crystalline nature of the furosemide. After compression at
2mT for 30% drug loaded batch showed overlapping peaks for furosemide. This
confirmed that there was no effect of compression force on polymorphic transformation
of furosemide but some peaks at 5.89, 12.05 and 14.15 degrees were suppressed.
This suppression might be due to change in the crystal habit during the
compression. In Figure 2-10 similar pattern of intense peaks were observed at 10.74,
13.18, 14.78, 16.47, 23.89 and 26.71 degrees for micronized griseofulvin particles before
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Figure 2-7.

MDSC thermograms of furosemide before and after compression
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Figure 2-8.

MDSC thermograms of griseofulvin before and after compression
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Figure 2-9.

X-ray powder diffraction of furosemide particles
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Figure 2-10. X-ray powder diffraction of griseofulvin particles
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and after compression with very weak suppression of peak intensities were observed after
compression. This demonstrates the speculation of no polymorphic transformation during
compression at 2mT compression force with 30% drug loading and also maintained the
crystallinity of both the API’s.
2.3.6

Effect of diluent particle size

Surface area and particle size distribution of two fractions of diluents, spray dried
lactose and DiTab® were presented in Table 2-5. Gas adsorption technique results
showed for the small size fractions of diluents showed larger specific surface area and
larger size fractions showed small specific surface area. Effect of these size fractions on
agglomeration of furosemide particles at 2mT compression force with 30% drug loading
is presented in Figure 2-11. Blend of fraction- 2 with larger particle size and smaller
specific surface area showed increase in size of furosemide particles during compression.
This increase in drug particle size might be due to smaller surface area available for
deposition of micronized drug on the surface of diluents. However, the diluents blend of
fraction-1 with smaller particle size with larger specific surface area significantly
(p<0.05) reduced the agglomeration of drug particles during compression and this might
be due to availability of more contact area which prevention of drug-drug particle
binding.
2.3.7

Dissolution studies

Generally dissolution rate also depends on the polymorphic forms of the drugs.
High energies are needed in transition of the molecule into solution in the crystalline
forms compared to transition of molecules in amorphous forms. Hence, the amorphous
forms dissolve faster. However, dissolution of crystalline drugs may also change
conversely due to imperfections generated during compression. So the energy required
for transition into solution from these crystals may decrease and results in the increase in
dissolution rate.102-104 Change in the dissolution rate distinctly can be observed at higher
compression forces. The dissolution of particles after compression was studied rather
tablets in this study to avoid any effect of compression force. Dissolution studies of
furosemide and griseofulvin particles are presented in the Figures 2-12 and 2-13
respectively. The dissolution study of unprocessed bulk furosemide particles was not
successful due its hydrophobic nature hence hinders the wetting of the particles.
Furosemide particle sizes 16.16 and 81.34 µm were selected as a representative
particle size for powder dissolution study from diluents (DiTab) size effect study. The
agglomerates of furosemide formed during compression at 2mT with 30% drug loading
were selected to evaluate particle size on dissolution rate instead tablets dissolution
because the surface of these particles will be directly available to dissolution media. The
rate of dissolution and the amount dissolved during study was slow and small for larger
particles compared to smaller particles of furosemide. Around 56% of smaller size
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Table 2-5.

Powder properties of diluents fractions

Diluent
Calcium phosphate di
hydrate
(DiTab)

Physical property

Spray dried lactose

Particle size(µm)
Surface area
(m2/gm)

Particle size
(µm)
Surface area
(m2/gm)

a-(mean ± sd, n=3)
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Fraction-1
37.90 ± 0.31a

Fraction-2
215.01 ± 0.24a

1.0318

0.5889

92.36 ± 0.59a

233.30 ± 19.45a

1.43

0.0931

Figure 2-11. Effect of particle size of diluents on furosemide during compression at
2mT with 30% drug loading

41

Figure 2-12. Dissolution of furosemide particles
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Figure 2-13. Dissolution of griseofulvin particles
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particles were dissolved within 5 min whereas only 36% was dissolved for larger size
agglomerates. Similar results were observed for griseofulvin powder particles.
Irrespective of the presence of wetting agent in the dissolution media and processing of
the different size powders of griseofulvin agglomerates showed difference in dissolution.
Approximately 12% of micronized griseofulvin particles got dissolved within 5 min but it
took 30 min to dissolve same amount of large particles of griseofulvin. This decrease in
dissolution clearly evident that hydrophobic micronized drug particles agglomerates
during compression which altered the dissolution rate instead of enhancing.
2.3.8 Drug-drug bonding mechanism
For evaluating the bonding mechanism in drug-drug particle agglomeration
micronized griseofulvin was selected due to its better compressible nature compared to
furosemide. To avoid dissolution of griseofulvin during soaking of the compacts the
media was pre saturated with it and its concentrations were presented in the Table 2-6.
All the tablets were soaked in this media and tensile strength was measured after drying.
Traditionally, based on the literature, assessment of tensile strength reveals what type of
bonding occurs during compression.50 Moderate increase in dielectric constant not likely
affect the solid bridge formation during compression, since solid bridges consists of
continuous phase of solid material. The limitation of this test is solubility of the material
at dielectric constants at greater extent which impacts the bonding structure of compacts.
According to Figure 2-14 the tensile strength of all the tablets at increased compressed
force were decreased initially and reached to plateau by increasing the dielectric constant
of the liquid media. This plateau might be due to inability of dissipate agglomerated
particles formed by solid bridge formation between the drug particles. Measurement of
tensile strength will give a better estimate for evaluating the solid bridge formation in the
compact. The tensile strength values at different dielectric constant media for griseofulvin
at various compression forces were not significantly different (p>0.05) except at 1 mT
compression force (p<0.05). The accurate measurement of solid bridge formation
between particles in the compact can be evaluated by calculating percent remaining
tensile strength of the compact after testing the crushing strength of the soaked and dried
tablets. Percent remaining tensile strength of the compact can be calculated by using
Equation 2-2.
=

× 100

(Eq. 2-2)
Where Ts (l) and Ts (a) are tensile strength of the compacts soaked in liquid and air
respectively. Figure 2-15 represents the percent remaining tensile strength vs. dielectric
constant. More than 60% remaining tensile strength was observed and this substantiates
the formation of solid bridge during compression of griseofulvin alone at different
compression force.
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Table 2-6.

Solubility of griseofulvin in organic solvents
Media

Dielectric constant

Solubility (mg/mL)

Air/ vacuum

1.00

NA

Hexane

1.89

0.010

n-Butanol

18.00

2.535

Ethanol

24.30

4.403
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Figure 2-14. Effect of dielectric constant and tensile strength
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Figure 2-15. Effect of dielectric constant on remaining tensile strength of compacts
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The percent remaining tensile strength of compacts was not proportional to with
the compression force. The remaining tensile strength of griseofulvin was significantly
higher at the plateau level which suggests the greater tendency for griseofulvin to form
solid bridges. Eriksson et al, described the variation in the predicted and actual tensile
strength of the compacts might be due to fracture mechanic effect or a high degree of
deformity of particles during compression. 105 Based on these results more energy is
required to break the formed agglomerates during compression of micronized
griseofulvin particles. The increase in tensile strength due to fragmentation and formation
of new surfaces can be ruled out since the starting particles itself are micron size.
2.4

Conclusions

In conclusion, the effect of compression force study on agglomeration of
micronized furosemide during compression showed significant increase in its particle size
compared to initial particle size but that increase was not significant among the
(consistent as compression force increased) compression forces. This consistent increase
after 1 mT compression force might be large enough to exceed the elastic limit of
furosemide particles that lead to breakage of furosemide aggregates by fracturing.
Increasing drug loading study for furosemide showed significant increase in furosemide
particle size during compression. 3 to 16 times increase from initial furosemide particles
in the effect of diluent particle size study on agglomeration of furosemide particles during
compression can be concluded that diluents with larger surface area (1.03 m2/gm or
smaller particle size (37.90 µm) are more suitable to avoid API agglomeration during
compression compared to diluents with larger size and smaller surface area. This might
be due to reduced adhesion of micronized API particles on large size/smaller surface area
diluents and higher deposition of API particles on smaller size/large surface area diluents
which provide more interparticulate contact area. Increasing the compression force and
drug loading study for griseofulvin particle agglomeration significantly increased the
particle size of griseofulvin during compression except at high drug loadings. The results
of the characterization studies SEM, thermal studies and powder x-ray diffraction for
furosemide and griseofulvin before and after compression concluded that high
compression forces modify the surface properties but had no effect on polymorphic
transformation during compression. The powder dissolution results for both the API’s at
different particles size showed effect of surface area exposed to dissolution media. The
dominating bonding mechanism responsible for agglomerate formation was found to be
solid bridge formation between API particles during compression.
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CHAPTER 3. PREVENTION OF DRUG-DRUG PARTICLE
AGGLOMERATION DURING COMPRESSION
3.1

Introduction

During the tablet compression the formula composition and the arrangement of
the various particles and their nearest neighbor contacts in the die influence the bonding
which occurs. Micronized or nano sized particles of hydrophobic drugs can agglomerate
into larger particles due to their inter-particular bonding of various types between these
particles during tablet compression. Agglomeration of these drug particles can be
prevented by treating these particles with particle agglomeration inhibitors (PAI) and/or
by using various processing techniques like roller compaction and spray drying before
compression.
The desirable characteristics of PAI’s such as nonionic block copolymer, waxes,
low melting polyethylene glycols and these should not interact chemically with the active
pharmaceutical ingredients. PAI’s should possess good wetting properties, soft (low
melting point), large surface area (small in size), hydrophilic (high HLB) in nature and
should possess excellent compressibility. Various methods such as film coating of
crystals, dispersion coating with soluble film former can reduce generation of hot spots
which affects adhesion during compression.106A common process in pharmaceutical
industry for manufacturing of tablets is powder mixing. Powder mixtures are classified
into two major groups, free-flowing mixtures, and mixtures containing interactive
constituents.107
Chiou et al. found a marked increase in dissolution rate for griseofulvin with PEG
dispersions. The physical nature of these systems was not well characterized. This
marked increase in dissolution was due to the decreased particle size in this molecularly
or colloidally dispersed griseofulvin in matrices of polyethylene glycol polymers.108
Gonnissen et al. described the change in the physical properties of various drugs,
particularly surface properties by co-processing with excipients together using spray
drying technique. This platform technology can be useful in developing ready-tocompress powder mixtures to improve poor compactability of drugs.109,110 According to
Makai et al. spray drying with alginates and lactose showed marked increase in the
polarity of the surface of the particles.111 Granules containing too high concentration of
super disintegrant can slow down the drug release from tablets due to viscous barrier
surrounding the particles.112
Expensive and time consuming process such as co-micronization of fenofibrate a
poor bioavailable antihyperlipoproteinemic agent improved the bioavailability
significantly greater extent with solid surfactant (sodium luaryl sulfate) than that simply
adding to formulation. Adsorption of surfactants on the surface of the solid is very
important for various applications.
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Recently roller compaction, a dry granulation process has been commonly used
for improving the dissolution rate of hydrophobic drugs. Mitchell et al. describes the
roller compaction with HPMC for poorly soluble drugs enhanced the dissolution rate due
to its micro environmental surfactant mechanism.113
Two hydrophobic micronized furosemide and griseofulvin were selected as model
drugs. Micronized furosemide and griseofulvin were individually compressed into tablets
along with surface active gents having large surface area and good wetting and
compressible properties. Today nanotechnology is increasing interest. Development of
tablet formulation with nano sized particles is a challenging task due to aggregation of
these particles during compression. Thus, very few tablet products with low dose are
currently available in the market based on the nanocrystal technology.
The objective of this study was to study the effect of various surface active agents
and various processing methods like physical mixing, roller compaction and spray drying
in prevention of drug-drug particle agglomeration during compression. Effect of
compression force also evaluated after treating the API with above mentioned methods
and particle agglomeration inhibitors (PAI). Particle sizes of these drugs were measured
before and after compression as the primary distinguishing evaluation parameter in this
work.
3.2

Materials and Methods

3.2.1 Materials
Furosemide (micronized API) was purchased from Teva Pharmaceuticals, Israel.
Micronized griseofulvin was a generous gift from Wuhan Yuancheng Technology, China.
Modified spray dried lactose 315 (Foremost® NF Lactose) was purchased from Foremost
Forms, Baraboo, WI. Mannitol SD 200, hydroxy propyl starch (Lycoat RS 720) were gift
samples from Roquette America Inc, Geneva, IL. Croscarmellose sodium (Ac-Di-Sol®)
was obtained from FMC biopolymer, Philadelphia. Poloxamer 188 (Lutrol® micro 68)
was obtained as a gift sample from BASF Corporation, New Jersey. Polyethylene glycol
(PEG 3350) was obtained from Dow chemicals, USA. Sodium benzoate was purchased
from Spectrum Chemicals Manufacturing Corporation, California. Magnesium stearate
was purchased from Mallinckrodt, New Jersey.
3.2.2 Methods
3.2.2.1

Effect of physical mixing

Initially API’s and PAI’s were mixed together geometrically and passed through #
60 stainless steel mesh along with spray dried lactose monohydrate and mixed together

50

by geometric mixing by passing through #60 stainless steel mesh twice and finally AcDi-Sol was blended in a plastic bag for 5 min. All the materials were accurately weighed
according to formulation in Tables 3-1 to 3-5.
3.2.2.2

Effect of roller compaction

The blend of API and PAI was prepared to prevent API-API agglomeration
during compression by roller compaction. To increases the API-PAI contact during
processing and to avoid segregation the API was blended with PAI which has larger
surface area and smaller in particle size than the unmodified PAI. To obtain smaller
particles of PEG 3350 the bulk PEG 3350 was sifted through mesh # 100 and a fraction
of particle size range less than 149µm was collected. For micronized Lutrol F68 the
supplier provided the average particle size of 50 µm. Similarly spray dried lactose from
bulk was selected by sieving through a stack containing mesh # 80 and mesh #200. The
fraction that passed through mesh #80 and retained on mesh #200 was selected for this
study. For preparation of blend for roller compaction initially the micronized
griseofulvin/furosemide and PEG 3350/ Lutrol F68 micro were blended by passing
through mesh # 140 (105 µm) based on drug to particle agglomeration inhibitor ratios
mentioned in the Table 3-4 and Table 3-5.
The pre-blend was made into ribbons using TFC-Labo (Vector Corporation) mini
roller compactor. Compaction pressure was adjusted to 5MPa and roll speed was kept at
2 rpm and 20 rpm feed rate was adjusted to feed blend. Thick and uniform ribbons were
produced with above parameters and the ribbons were passed through a # 40 mesh screen
and blended with spray dried lactose and Ac-Di-Sol for15 minutes before compression.
3.2.2.3

Effect of spray drying

A suspension of micronized furosemide was prepared by weighing 2 parts of
Mannitol and 1 part of micronized furosemide in 100 mL of distilled water and stirred for
4 hrs to obtain a homogeneous suspension. The suspension was spray dried using a
BUCHI-290 (Switzerland) spray dryer with 150°C inlet and 95°C outlet temperature; the
aspirator capacity was 100%, the feed rate was 20% and 60 ml/hr of airflow. Mannitol
and furosemide co-processed powder was collected in cyclone separator. For comparison
another batch of physical blend was prepared according to the formulation given in Table
3-6 and compressed into tablets at various compression forces. The co-processed powder
was blended with remaining excipients present in Table 3-7 and compressed into tablets.
Preparation procedure for co-processed powder is given in Figure 3-1. Similarly a
furosemide suspension was prepared by weighing 5 parts of micronized furosemide and 1
part of hydroxyl propyl starch (Lycoat RS 720) in 100 ml of distilled water and stirred for
4 hrs to get homogenous suspension.
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Table 3-1.

Formulations for effect of physical mixing on griseofulvin particles

Ingredients

F-1

F-2

F-3

F-4

F-5

F-6

Griseofulvin (%)

30.00

30.00

30.00

30.00

30.00

30.00

PEG 3350 (%)

15.00

30.00

60.00

-

-

-

-

-

-

15.00

30.00

60.00

54.00

39.00

9.00

54.00

39.00

9.00

Ac-Di-Sol (%)

1.00

1.00

1.00

1.00

1.00

1.00

Total (%)

100.00

100.00

100.00

100.00

100.00

100.00

Lutrol F68 micro
(%)
Spray dried lactose
(%)
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Table 3-2.

Formulations for effect of physical mixing on furosemide particles

Ingredients

F-20

F-21

F-22

F-23

F-24

F-25

Furosemide (%)

10.00

20.00

30.00

10.00

20.00

30.00

-

-

-

5.00

5.00

5.00

89.90

79.90

69.90

84.90

74.90

64.90

Ac-Di-Sol (%)

0.10

0.10

0.10

0.10

0.10

0.10

Total (%)

100.00

100.00

100.00

100.00

100.00

100.00

Lutrol F68 micro
(%)
Spray dried lactose
(%)
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Table 3-3.
particles

Formulations for effect of physical mixing of PEG 3350 on furosemide

Ingredients

F-28

Furosemide (%)

10.00

PEG 3350 (%)

10.00

Spray dried lactose (%)

79.90

Ac-Di-Sol (%)

0.10

Total (%)

100.00
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Table 3-4.

Formulations for effect of roller compaction on griseofulvin particles

Ingredients

F-7

F-8

F-9

F-10

F-11

F-12

Griseofulvin (%)

30.00

30.00

30.00

30.00

30.00

30.00

PEG 3350 (%)

15.00

30.00

60.00

-

-

-

Lutrol F68 micro (%)

-

-

-

15.00

30.00

60.00

39.00

9.00

54.00

39.00

9.00

1.00

1.00

1.00

1.00

1.00

100.00

100.00

100.00

100.00

Spray dried lactose (%) 54.00
Ac-Di-Sol (%)
Total (%)

1.00

100.00 100.00
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Table 3-5.
Formulations for effect of physical mixing and roller compaction on
furosemide particles
Ingredients

F-26(Physical mixing)

F-27 (Roller compaction)

Furosemide (%)

20.00

20.00

Lutrol F68 micro (%)

20.00

20.00

Spray dried lactose (%)

59.90

59.90

Ac-Di-Sol (%)

0.10

0.10

Total (%)

100.00

100.00
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Table 3-6.
particles

Formulations for effect of physical mixing of mannitol on furosemide

Ingredients

F-13

F-14

F-15

Furosemide (%)

10.00

20.00

30.00

Mannitol SD 200 (%)

89.90

79.90

69.90

Ac-Di-Sol (%)

0.10

0.10

0.10

Total (%)

100.00

100.00

100.00
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Table 3-7.
particles

Formulations for effect of spray drying with mannitol on furosemide

Ingredients

F-16

F-17

F-18

Furosemide (%)

10.00

20.00

30.00

Mannitol SD 200 (%)

89.90

79.90

69.90

Ac-Di-Sol (%)

0.10

0.10

0.10

Total (%)

100.00

100.00

100.00
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Figure 3-1.
furosemide

Preparation procedure for co-processed powder of mannitol and

59

Furosemide and Lycoat RS 720suspension was spray dried at 100°C inlet and
80°C outlet temperature; aspirator capacity was 100% and feed rate of 20% and 60 ml/hr
airflow. The co-processed powder was collected in cyclone separator and blended with
remaining excipients presented in Table 3-8. The final blend was compressed into tablets
at various compression forces. Procedure for preparation of co-processed powder is
presented in Figure 3-2.
3.2.2.4

Effect of level of super disintegrant

The effect of the level of super disintegrant was evaluated for preventing the
agglomeration of API during compression. Micronized furosemide and spray dried
lactose monohydrate were accurately weighed by varying the Ac-Di-Sol levels according
to Table 3-9. Initially furosemide and spray dried lactose monohydrate were
geometrically mixed together on paper and by passing through #60 stainless steel mesh
twice. Finally Ac-Di-Sol was blended in a plastic bag for 5 min. the final blend was
compressed into tablets at various compression forces. The compressed tablets were
disintegrated in a furosemide saturated medium and particle size of furosemide after
disintegration was estimated by light scattering technique. Saturated furosemide solution
was used as medium for particle size measurement. Six portions of blend (200 mg each)
were individually weighed and compressed for each level of compression force.
3.2.2.5

Effect of hexane treatment

Based on the formulation micronized furosemide and spray dried lactose
monohydrate were accurately weighed and dispersed in 150 ml of hexane and stirred
using magnetic stirrer for 4 hours to make a slurry (furosemide and lactose were insoluble
in hexane). The slurry was dried while stirring under fume hood in a crucible. The dried
residue was further dried under vacuum oven at 60°C for 24 hours to get rid of any
residual hexane. The residue was characterized for surface morphology by using
Scanning Electron Microscopy. Final blend was prepared based on the formulation in
Table 3-10.
3.2.2.6

Compression of tablets

Tablets of weight 200 mg for furosemide and 400 mg for griseofulvin were
compressed on a Carver hydraulic manual bench top laboratory press (Model C, Carver,
Inc) with dual scale gauge. 5/16” FFBE (flat face bevel edge) for furosemide and 3/8” FF
(flat face) for griseofulvin tooling were used with 7.93 mm and 9.5 mm diameter tooling
was used respectively. Lubricant, magnesium stearate was applied externally to the faces
of upper and lower punches before each tablet compression.
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Table 3-8.
Formulations for effect of spray drying with Lycoat RS 720 on
furosemide particles
Ingredients

F-19

Furosemide (%)

30.00

Lycoat RS 720 (%)

1.00

Mannitol SD 200 (%)

68.90

Ac-Di-Sol (%)

0.10

Total (%)

100.00
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Figure 3-2.
720 powder

Preparation procedure for co-processed furosemide and Lycoat RS
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Table 3-9.

Formulations for level of super disintegrant

Ingredients

F-29

F-30

F-31

Furosemide (%)

30.00

30.00

30.00

Spray dried lactose (%)

69.90

69.00

68.00

Ac-Di-Sol (%)

0.10

1.00

2.00

Total (%)

100.00

100.00

100.00
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Table 3-10.

Formulation for hexane treatment effect for furosemide
Ingredients

F-32

Furosemide (%)

30.00

Spray dried lactose (%)

69.90

Ac-Di-Sol (%)

0.10

Total (%)

100.00
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3.2.2.7

Disintegration of tablets

Disintegration of tablets was done in QC-21™ disintegration test system in
saturated drug solution at room temperature. The disintegration was continued further for
another one hour after disintegration of tablets to dissolve all soluble excipients in the
media. The residue was collected by vacuum filtration unit with 0.45µm nylon filters and
proceeds further for particle size measurement and characterization.
3.2.2.8

Particle size analysis

A Saturn Digisizer® 5200, a high resolution laser particle size analyzer attached
with low volume liquid sampling handling unit, was used to measure the particle size of
the residue after the disintegration study. The low volume LSHU holds only 100 ml of
saturated medium for carrying the sample and the circulation pump rate was adjusted to
6L per minute. Each sample was analyzed three times. Saturated furosemide solution for
furosemide samples and saturated griseofulvin solution for griseofulvin samples was used
as dispersion media to measure the particle size. A small suspension sample was prepared
in saturated drug solution to measure the particle size of the drug residue obtained after
disintegration process. Particle size data obtained after compression at various
compression forces and treatments were subjected to a student t test and p-values were
presented.
3.2.2.9

Modulated differential scanning calorimetry

Modulated Differential Scanning Calorimetric (MDSC) studies were carried out
to confirm the polymorphic changes in furosemide and griseofulvin in the samples during
processing and tablet compression using a Q2000 DSC (TA instruments). The data were
analyzed using Universal Analysis software. Thermograms reverse heat flow was plotted
against temperature.
3.2.2.10

Scanning electron microscopy studies

Surface morphologies of particles were studied using an environmental scanning
electron microscope (SEM). SEM evaluation was conducted by spreading samples onto
double-sided adhesive carbon tape on an aluminum stub. A thin coating (~ 25 nm) of gold
was applied on to the sample using a Hummer VII Sputtering System and the coated
sample stubs were mounted and focused under ESEM XL 30 (FEI). All the samples were
observed at an energy of 30 KV and various magnifications.
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3.3

Results and Discussion

3.3.1 Effect of physical mixing
Effect of physical mixing of griseofulvin and Particle Agglomeration Inhibitors
(PEG 3350/Lutrol F68 micro) at various ratios’ on micronized griseofulvin particles
during compression is presented in Figures 3-3 and 3-4. Both the PAI’s showed decrease
in the particle agglomeration of griseofulvin as the ratio of GSF to PAI decreases when
compared to without PAI. The micronized griseofulvin particles with mean particle size
of 13.96 ± 0.23 µm were increased to 55.00 ± 7.2 µm and 111.46 ± 5.7µm without PAI at
30% drug loading compressed at 1.0 and 2.0 mT forces respectively. After physical
treatment with PEG 3350 in F-1(1:0.5), F-2( 1:1) and F-3 (1:2) formulations, the
micronized griseofulvin particles agglomerates with mean particle size of 46.59 ± 2.28
µm, 60.64 ± 1.33 µm and 50.99 ± 2.35 µm at 1mT compression force and 72.06 ± 2.49
µm, 68.25 ± 1.46 µm and 60.13 ± 2.13 µm at 2mT compression force respectively with
30% drug loading.
Similarly by physical treatment with Lutrol F68 micro a nonionic block copolymer in the formulations F-4 (1:0.5), F-5 (1:1) and F-6 (1:2) decreased the
agglomeration of micronized griseofulvin particles during compression at 1mT and 2 mT
compared to without PAI treatment. The mean particle size of griseofulvin after physical
treatment with Lutrol F68 micro was found to be 37.05 ± 2.56 µm, 32.50 ± 3.06 µm and
21.88 ± 0.91 µm at 1mT compression force and 52.77 ± 1.15 µm, 37.17 ± 2.51 µm and
35.39 ± 0.99 µm at 2mT compression force respectively with 30% drug loading.
Combination of properties like high surface area, low melting point and superior surface
active properties of Particle agglomeration inhibitors (PEG 3350 and Lutrol F 68 micro)
might be responsible in reducing the agglomeration of micronized griseofulvin particles
during compression.
Shah et al. described the high energy ordered mixtures provide the more
advantages than simple ordered mixtures in deaggregation of cohesive drugs by
improving the efficiency of high surface area carrier and hydrophilic nature of lactose.114
Figure 3-5 represents the particle size of furosemide agglomerates formed during
compression of formulations without PAI (F-20, F-21 and F-22) and with Lutrol F68
micro (F-23, F-24 and F-25). In Formulations F-23 to F-25, furosemide was physically
mixed with Lutrol F68 micro (PAI) at decreasing ratios of drug to PAI (0.5 to 0.17).
Micronized furosemide agglomeration during compression was decreased with
decreasing ratios of drug to PAI. Treatment with Lutrol F68 micro, the 5.04 µm sized
furosemide was agglomerated only from to 10.82 ± 3.1 µm, 49.66 ± 1.03 µm and 89.52 ±
3.79 µm at furosemide to Lutrol ratio 0.5, 0.25 and 0.17 after compression at 2mT
compression force respectively. The percent reduction in the agglomeration of
micronized furosemide during compression in the presence of Lutrol F68 micro presented
in the Figure 3-6.
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Figure 3-3. Effect of physical mixing with PEG 3350 on griseofulvin particles
during compression
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Figure 3-4. Effect of physical mixing with Lutrol F68 on griseofulvin particles
during compression
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Figure 3-5. Effect of physical mixing of Lutrol F68 micro on furosemide particles
during compression
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Figure 3-6. Effect of ratio of level of Lutrol F68 micro on agglomeration of
furosemide particles during compression
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Prevention of agglomeration during compression of furosemide particles was
achieved by physical treatment with PEG 3350 in formulation F-28 at 1:1ratio of API to
PAI and the mean particle size of agglomerates were 8.42 µm and 21.09 µm at 1mT and
2.0 mT respectively.
3.3.2

Effect of roller compaction

SEM images of griseofulvin particles, after roller compaction treatment with
Lutrol F68 micro and PEG 3350 are presented in Figure 3-7(a), (b) and (c) respectively.
Effect of roller compaction of griseofulvin and Particle Agglomeration Inhibitors (PEG
3350/Lutrol F68 micro) at various ratios’ on micronized griseofulvin particles during
compression is presented in Figures 3-8 and 3-9. Both the PAI’s showed decrease in the
particle agglomeration of griseofulvin as the ratio of GSF to PAI decreases. The
micronized griseofulvin particles with mean particle size of 13.96 ± 0.23 µm were
increased to 55.00 ± 7.2 µm and 111.46 ± 5.7µm with 30% drug loading at 1.0 and 2.0
mT compression forces respectively. After roller compaction treatment with PEG 3350 in
F-7(1:0.5), F-8( 1:1) and F-9 (1:2) This is decreasing ratio of GSF to PAI formulations
the micronized griseofulvin particles agglomerates with mean particle size of 74.17 ±
6.10 µm, 77.22 ± 4.98 µm and 29.68 ± 0.96 µm at 1mT compression force and 78.19 ±
4.23 µm, , 79.99 ± 3.34 µm and 47.00 ± 1.95 µm at 2mT compression force respectively
with 30% drug loading. The interference of point to point contact and the low melting
point of PEG 3350 and its surface active properties might be responsible for reduction in
the agglomeration of micronized griseofulvin particles during compression.
Similarly by roller compaction treatment with Lutrol F68 micro a nonionic block
co-polymer in the formulations F-10 (1:0.5), F-11 (1:1) and F-12 (1:2) decreased the
agglomeration of micronized griseofulvin particles during compression at 1mT and 2 mT
compared to without PAI. The mean particle size of griseofulvin after roller compaction
treatment with Lutrol F68 micro was found to be 40.89 ± 0.92 µm, 53.93 ± 2.04 µm and
40.03 ± 2.01 µm at 1mT compression force and 62.28 ± 1.46 µm, 49.58 ± 1.43 µm and
32.00 ± 1.02 µm at 2mT compression force respectively with 30% drug loading.
Effect of physical treatment with very low percent (5%) of Lutrol F68 micro for
furosemide in prevention of agglomeration during compression was found to be
successful. Agglomeration of micronized furosemide during compression at 1mT and
2mT forces for Formulations F-26(physical treatment) and F-27 (roller compaction
treatment) at 1:1 ratio of API to PAI (Lutrol F68 micro) was found to be much less. The
mean particle size of agglomerated furosemide in Figure 3-10 during compression was
21.88 ± 5.6 µm, 29.37 ± 2.00 µm and 8.97 ± 3.02 µm and 36.23 ± 2.57 µm at 1mT and
2mT forces respectively. This low melting point nature and more uniform spreading of
Lutrol F68 micro during roller compaction might be responsible for preventing drug-drug
agglomeration during compression process.
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Figure 3-7. SEM image of (a) griseofulvin API particles (b) roller compacted
griseofulvin + Lutrol F68 micro (c) roller compacted griseofulvin + PEG 3350
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Figure 3-8.

Effect of roller compaction with PEG 3350 on griseofulvin particles
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Figure 3-9.
particles

Effect of roller compaction with Lutrol F68 micro on griseofulvin
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Figure 3-10. Effect of physical mixing and roller compaction with Lutrol F68
micro on furosemide particles during compression
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3.3.3
3.3.3.1

Effect of spray drying
Mannitol SD 200

Figure 3-11(a) and (b) represents the particle size distribution of furosemide
before compression and after compression of formulation F-15 at 2 mT respectively. The
particle size distribution was represented in volume frequency percent. The mean particle
size of furosemide before compression was found to be 5.04 ± 0.5 µm. The size
distribution curve for micronized furosemide showed a bi-modal distribution. Scanning
electron microscopic images in Figure 3-12(a) represents micronized furosemide before
compression. The effect of physical mixing with mannitol SD 200 on particle size of
micronized furosemide during compression was evaluated by compressing the physical
blend of furosemide at various compression forces for formulations F-13 (10% drug
loading), F-14 (20% drug loading) and F-15 (30 % drug loading). The micron size
furosemide particles agglomerates into large chunks during compression with mean
particle size range of 28.3 ± 0.46, 37.02 ± 0.97, 44.68 ± 0.38, and 46.77 ± 1.83 µm at 0.5,
1.0, 1.5 and 2.0 mT compression forces for formulation F-13 (10 % drug loading)
respectively. For formulation F-14 with 20% drug loading these micronized furosemide
particles agglomerates into 55.21 ± 3.1, 66.06 ± 2.51, 74.57 ± 2.76 and 83.05 ± 2.97 µm
at 0.5, 1.0, 1.5 and 2.0 mT compression forces respectively. Similarly, for formulation F15 these drug particles agglomerates into 76.13 ± 3.25, 120.9 ± 7.25, 117.9 ± 16.67 and
128.7 ± 7.51 µm. Figure 3-12(b) represents furosemide particles after compression at 2
mT for formulation F-15(30% drug loading). Furosemide particles before compression
were polygonal structure, cubical and rod in shape after compression these particles
formed large agglomerates with narrow distribution shown in Figure 3-12. SEM image
of furosemide was also correlating with the respective distributions before and after
compression. Surface morphology of furosemide particles after compression was changed
to rough, large chunks of agglomerates. Figure 3-13 represents effect of compression
force and drug loading on furosemide particles with mannitol as a diluent by physical
mixing.
Spray drying treatment of micronized furosemide with mannitol SD 200 reduced
the agglomeration of furosemide particles during compression. SEM images in Figure
3-14(a) to (d) represents alone Mannitol SD 200 before spray drying, furosemide +
Mannitol SD 200 particles after spray drying, micronized furosemide API particles before
spray drying and after compression at 2mT of spray dried blend of furosemide +
Mannitol SD 200 formulation (F-18) respectively. The spherical shape Mannitol SD 200
in Figure 3-14(a) did not altered its shape even after spray drying the suspension of
furosemide in Figure 3-14(b). Spray drying with Mannitol SD 200 successfully reduced
the agglomeration of micronized furosemide during compression for the formulations F16 (10% drug loading), F-17 (20% drug loading) and F-18 (30% drug loading). The mean
particle size of agglomerated furosemide particles after compression of formulation F-16
was 8.44 ± 0.63 µm, 9.46 ± 0.21 µm, 10.24 ± 0.29 µm and 10.98 ± 0.55 µm at 0.5, 1.0,
1.5 and 2.0 mT compression forces respectively. Compression of Formulation F-17 at
0.5, 1.0, 1.5 and 2.0 mT forces agglomerates into 24.51 ± 0.78 µm, 25.86 ± 0.65 µm,
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Figure 3-11. Particle size distribution of furosemide particles (a) before
compression (b) after compression at 2mT with 30% drug loading
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Figure 3-12. SEM image of furosemide particles (a) before compression (b) after
compression (F-15)
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Figure 3-13. Effect of compression force and drug loading furosemide particles
with mannitol as a diluent by physical mixing
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Figure 3-14. SEM image of (a) mannitol SD 200 particles (b) mannitol SD 200 +
furosemide after spray drying (c) furosemide particles (d) furosemide particles after
compression (F-18)
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12.1± 0.45 µm and 20.83 ± 4.11µm respectively. SEM image of furosemide particles
after compression at 2mT for formulation F-18 is presented Figure 3-14(d).Similarly the
Formulation F-18 aggregates into mean particle size of 29.4 ± 5.95 µm, 33.99 ± 2.72 µm,
23.56 ± 7.74 µm and 28.26 ± 1.16 µm at 0.5, 1.0, 1.5 and 2.0 mT respectively. Figure
3-15 represents effect of compression force and drug loading on furosemide particles by
spray drying process.
3.3.3.2

Lycoat RS 720

SEM image of furosemide in Figure 3-16 shows (a) pure API particles and (b)
Spray dried sample of furosemide with hydroxy propyl starch (Lycoat RS 720). The
images of spray dried mixture shows that micronized furosemide was coated by thin layer
of hydroxy propyl starch which is specifically designed for aqueous film coating of
immediate release solid dosage forms. Compression of blend containing coated mixture
and remaining excipients in the formulation F-19 at 0.5, 1.0, 1.5 and 2.0 mT force results
in the agglomerates of furosemide particle with mean particles size of 16.91 ± 0.16 µm,
16.83 ± 0.53 µm, 15.27 ± 0.23 µm and 17.82 ± 0.62 µm respectively. Figure 3-17
represents effect of spray drying of furosemide with Lycoat RS 720 on furosemide
particles during compression. Based on these results aqueous film coating by spray
drying process with hydroxyl propyl starch + micronized furosemide particles
successfully prevented the aggregation during compression. This might be due to fast
dispersible nature and easy film formation in aqueous environment of hydroxy propyl
starch.
3.3.4

Effect of concentration of super disintegrant

Incorporation of large percentage of super disintegrant in the formulation can
prevent agglomeration of micronized drug particles during compression. However, the
cost of the super disintegrant and formulation issues like stability, drug release needs to
consider in adopting high percentage of super disintegrants in the formulation. The
micronized furosemide particles in the formulations F-22, F-30 and F-31 agglomerated
during compression with 30 % drug loading and presented in the Figure 3-18. The mean
particle size of formed agglomerates of furosemide with low levels of super disintegrant
(0.1%) were 139.5± 6.8 µm and 150.1 ± 17.7 µm at 1mT and 2mT compression force
respectively. Similarly with increasing levels of super disintegrant 1.0 % and 2% of AcDi-Sol in the formulations F-30 and F-31, the micronized furosemide particles
agglomerated with the mean particle size of 61.58 ± 4.11µm, 84.64 ± 4.78 µm and 64.1 ±
3.5 µm, 74.07 ± 4.98 µm at 1mT and 2mT compression force respectively. These results
showing that increasing the concentration of super disintegrant in the formulation could
not fully prevent the agglomeration of micronized furosemide particles during
compression at 30% drug loading. However some particle agglomeration was prevented
with increasing levels of super disintegrant. The capillary action of superdisintegrant at
high concentration during disintegration of tablets might be responsible for this reduction
in the particle size of agglomerates.
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Figure 3-15. Effect of compression force and drug loading on furosemide particles
by spray drying process
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Figure 3-16. SEM image (a) furosemide particles (b) furosemide + Lycoat RS 720
spray dried particles
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Figure 3-17. Effect of spray drying of furosemide with Lycoat RS 720 on
furosemide particles during compression
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Figure 3-18. Effect of AC-Di-Sol concentration on furosemide particles during
compression
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3.3.5 Effect of hexane treatment
Agglomeration of micronized furosemide during compression can be prevented
by treating with Hexane. The SEM images in the Figure 3-19(a) to (c) shows furosemide
coated spray dried lactose particles after hexane treatment at 400X, 200X and 6400X
magnification respectively. The dried slurry of hexane shows uniform coating of
micronized furosemide on large particles of spray dried lactose which could help in
preventing drug-drug particle agglomeration during compression. Figure 3-20 shows the
effect of hexane slurry treatment of furosemide particles after compression and
disintegration. The mean particle size of agglomerates in formulation F-32 were found to
be 56.70 ± 5.42 µm and 97.64 ± 17.36 µm with 30% drug loading at 1mT and 2mT force
respectively. Hexane treatment helped some extent in preventing agglomeration during
compression compared to without treatment (F-22). This might be due to uniform
distribution of micronized furosemide particles on the large size spray dried lactose
particles which might have created less contact area between drug particles during
compression.
3.3.6 Modulated differential scanning calorimetry
Thermograms in the Figure 3-21 represent comparison of furosemide particles
before compression and after compression. Treatment effect of on polymorphic changes
in furosemide particles during compression was compared and a change in the melting
point of furosemide was observed in physically treated and spray dried blends. This effect
might be due to small portion of PAI traces in the sample or amorphous conversion of
furosemide during treatment with PAI. Similarly the Figure 3-22 represents the
thermograms of furosemide particles after compression at 2mT using the blend
containing co-spray dried furosemide with Lycoat RS 720. Based on the MDSC results
spray coating of Lycoat RS 720 (which is an aqueous film former) on furosemide
particles did not show change any polymorphism of furosemide particles during
compression. The sharp melting point at 210.52°C in reverse heat flow in the Figures
3-21 and 3-22 represents the crystalline nature of furosemide. Sharp endotherm at
195.31°C represents the melting point of Lycoat RS 720 in Figure 3-22, which is absent
in the compressed and disintegrated tablets of blend containing Lycoat RS 720 spray
coated furosemide particles. The compression of tablets was done at 2mT force with 30%
drug loading. These thermograms were overlapping with the furosemide thermograms
represent no polymorphic change during compression or spray drying. The MDSC
thermograms in Figures 3-23 and 3-24 represent the effect of physical treatment and
roller compaction treatment with particle agglomeration inhibitors (PEG 3350, Lutrol
F68 micro) on griseofulvin particles during compression respectively.
The sharp endothermic peaks of griseofulvin at 218.58°C before and after
compression at 2mT with 1:0.5 ratio of drug to PAI’s shows a polymorphic change in
griseofulvin. This melting endotherm corresponds to the crystalline nature of griseofulvin
before and after compression but shift in the melting point might be due to impurities in
the material or conversion to amorphous griseofulvin.
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Figure 3-19. SEM images (a) 400X, (b) 200X, (c) 6400X magnification of
furosemide particles coated on lactose monohydrate particle in hexane slurry
treatment
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Figure 3-20. Effect of treatment with hexane on furosemide particles during
compression
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Figure 3-21. MDSC thermograms of furosemide particles after treatment with
mannitol spray dried
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Figure 3-22. MDSC thermograms of furosemide after particles after treatment
with Lycoat RS 720
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Figure 3-23. MDSC thermograms of griseofulvin after physical treatment with
PEG3350 and Lutrol F68

91

Figure 3-24. MDSC thermograms of griseofulvin particles after roller compaction
with PEG 3350 and Lutrol F68

92

3.4

Conclusions

In conclusion, furosemide and griseofulvin particles agglomeration during
compression was prevented by treatment with particle agglomeration inhibitors like PEG
3350 and Lutrol F68 micro. Treating the furosemide particles prior to compression with
Lutrol F68 micro by roller compaction process significantly (p<0.05) prevented more
agglomeration when compared to physical treatment with PAI’s. Modulated differential
scanning calorimetry studies provided the evidence of crystallinity and also effect of
PAI’s on polymorphic transformation during treatment and compression. Hexane
treatment for furosemide provided significant (p<0.05) prevention in agglomeration
during compression compared to without any treatment. Increasing level of super
disintegrant in preventing the agglomeration during compression study for furosemide
showed significant (p<0.05) prevention when compared at 0.1% to 1% and 2% but not at
1% to 2% (p>0.05) which shows its limitation. Spray drying with either mannitol or
hydroxyl propyl starch for micronized furosemide significantly (p<0.05) reduced the
agglomeration of API particles during compression. Similarly for griseofulvin physical
treatment with Lutrol F68 micro prevented the agglomeration significantly (p<0.05)
during compression more successfully whereas with PEG 3350 treatment the prevention
was not significant (p>0.05) at 1mT compression force compared to without any
treatment. Roller compaction with Lutrol F68 micro significantly (p<0.05) prevented the
agglomeration of griseofulvin during compression compared to without any treatment
whereas with PEG 3350 the prevention was not significant (p>0.05) at 1mTcompression
force. This increase in particle size of griseofulvin might be due to formation of
griseofulvin-PEG 3350 solid dispersions. Thermal studies revealed that treatment with
PAI’s and roller compaction processing with PAI’s affect the griseofulvin crystalline
nature. This polymorphic change might be due to formation of solid dispersion by either
treatment with PAI’s or during the compression.
In summary, agglomeration of micronized hydrophobic drugs during compression
can be prevented by treating with particle agglomeration inhibitors prior to compression.
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